Combatting Bacterial Resistance in Europe
September 2016
EPI-Net's Evelina Tacconelli
always wanted to be an infectious diseases physician because nothing in medicine is so “unique”, “attractive” and “emotionally rewarding” as ID.

Study Update EURECA

COMBACTE-CARE's EURECA study is progressing adequately. It is a very ambitious and challenging project involving 50 sites from 11 countries, aiming at including 2000 patients!

Increased Momentum in AMR Research

The Lancet has published a letter highlighting how the EU is tackling antimicrobial resistance. Authored jointly by IMI's Pierre Meulien as well as representatives of the European Commission, EFPIA, and the European Investment Bank.


Leading Center in recruitments is the University Hospital Virgen del Rocío in Seville (J. M. Cisneros Herreros & M.J. Hernández-Rodríguez) with 3 patients.

COMBACTE Country Visits

Kicking off with Bulgaria September 13-14th, CLIN-Net  and LAB-Net are pllanning country visits to all European countries involved in COMBACTE.

Success for EPI-Net


COMBACTE-MAGNET's EPI-Net has been very active over the last months and succeeded in establishing a network of scientists from academic, public health agencies, research foundations, and industry.

RESCUING Database Locked

A total of 1,009 evaluable cases have been collected with the final case entered on 17th July 2016. All queries were solved and the database was locked on  the 12th of August 2016.


COMBACTE CLIN-Net and LAB-Net Dashboards Now Live!

View our growing network here
Upcoming Events

Face to Face GCP Training

Where: Athens, Greece
When: 22 September
Duration: Two Day Event

COMBACTE Country Visit Italy

Where: Milan, Italy
When:  4th of October
Duration: Two Day Event
This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115523 | 115620 | 115737 resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution. 
New ideas for the next newsletter?
Contact the PMO team here
Update subscription preferences